Millennium Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-180,300
Closed -$4.31M 6353
2025
Q2
$4.31M Buy
+180,300
New +$4.54M ﹤0.01% 3147
2025
Q1
Sell
-544,700
Closed -$10.3M 6271
2024
Q4
$10.3M Buy
+544,700
New +$9.56M 0.01% 2156
2023
Q2
Sell
-11,200
Closed -$457K 6543
2023
Q1
$457K Buy
+11,200
New +$446K ﹤0.01% 4661
2017
Q3
Sell
-100,000
Closed -$4.77M 3773
2017
Q2
$4.77M Buy
+100,000
New +$4.64M 0.01% 1542
2015
Q3
Sell
-30,000
Closed -$2.12M 3662
2015
Q2
$2.12M Buy
+30,000
New +$2.36M ﹤0.01% 1886

Other funds holding PCRX

Millennium Management's PCRX Position: Q1 2026 in Review

Millennium Management reduced its Pacira BioSciences (PCRX) stake by 53% in Q1 2026, selling an estimated $1.46M and leaving 57,031 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4196.

Millennium Management first reported a position in PCRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $70.2M in Q3 2018. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Millennium Management held 57,031 shares of Pacira BioSciences worth $1.29M as of Q1 2026.
  • Millennium Management sold 65,575 Pacira BioSciences shares in Q1 2026, an estimated $1.46M.
  • Pacira BioSciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4196 holding.
  • Millennium Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 48 quarters since.
  • Millennium Management's Pacira BioSciences position peaked at $70.2M in Q3 2018.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.